MGC Pharmaceuticals on the front line of Psilocybin R&D (VIDEO)

oduction and development of innovative medicines for unmet medical needs, has announced that following shareholder approval at a General Meeting held on 25 October 2023, the consolidation of the Company’s total issued capital on a 1:1,000

MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of innovative medicines for unmet medical needs, is pleased to announce that following shareholder approval for a new share placement secured

MGC Pharmaceuticals Ltd (LON:MXC) has advised that is has released its 30 June 2023, Preliminary Financial Report, an unaudited Full Year Financial Report required under the Australian Securities Exchange’s Listing Rules. MGC Pharmaceuticals Limited (LON:MXC) is a

MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of plant derived medicines, has announced positive pre-clinical trial results from the recently completed Pre-clinical Chronic Toxicology Evaluation of 14 days oral

MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of plant derived medicines, has announced it has been granted its first import permit for 200g of Psilocybin Raw Mushroom material to

MGC Pharmaceuticals Ltd (LON:MXC), a European based pharmaceutical company specialising in the production and development of plant derived medicines, has provided its Quarterly Activity Report for the three months ending 30th June 2023. Key Highlights: ·      CannEpil®, MGC

MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has welcomed the new regulation in Australia making it the first country to allow psychiatrists to prescribe psychedelics to

MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has announced the appointment of Mr. Layton Mills as a Non-Executive Director of the Company effective immediately. Mr. Mills

MGC Pharmaceuticals Ltd (LON:MXC) a European based pharmaceutical company specialising in the production and development of plant inspired medicines, has announced that CannEpil®, MGC Pharma’s IMP has now been successfully imported and received by its first patients in

MGC Pharmaceuticals Ltd (ASX:MXC), a European based pharmaceutical company specialising in production and development of plant inspired medicines, has announced the following changes to the Board and its lead UK advisers, as a further development in its pharmaceutical